Modern therapy for classical APL with PML::RARA is considered to be a combination of ATRA and ATO which both lead to disruption of the fusion protein and restore the activity of the retinoic acid receptor pathway, unblock myeloid differentiation and decrease the proliferative capacity of abnormal cells [2,4,64,65,66]. The gene discussed is PML; the disease is acute promyelocytic leukemia.